Skip to content

Korsana Biosciences, Inc.

KRSA· NasdaqCore metricsCIK 1755237

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -0.92%
Market cap
$1.43B
45.54M shares
Filings
398
$0.00
Q2 2026+3.7% FY25 yoy
-$46.43M
Q3 2026N/M FY25 yoy
-$48.27K
Q3 2026N/M FY25 yoy
-$49.73M
Q3 2026derivedN/M FY22 yoy
-$3.19
Q3 2026N/M FY25 yoy
$456.22M
Q3 2026+4,669.0% FY25 yoy
$1.43B
—
688.2×
3.6×
—
—

FY2025 figures · derived

Price

$31.34+33.25%+$7.82since Sep 8, 2026
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.07MFY 2025
$4.51M0FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$2,074,000reported
FY 20242024-12-31$2,000,000reported
FY 20232023-12-31$0reported
FY 20222022-12-31$297,000 revisedreported
FY 20212021-12-31$3,942,000reported
FY 20202020-12-31$2,296,000reported
FY 20192019-12-31$4,507,000reported

Segments

Products
Revenue by Products, FY2023 to FY2024FY2023FY2024Revenue from license agreement · FY2024 · $1.75MOption to license revenue · FY2024 · $250.00K
LineFY2024ShareChange
Revenue from license agreement$1.75M88%—
Option to license revenue$250.00K13%—
Total$2.00M

From the 10-K filed Mar 4, 2025KRSA

Pharmaceutical preparations

Korsana Biosciences, Inc. is the 200th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Korsana Biosciences, Inc. · CIK 1755237 · Engraved from SEC EDGAR